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The administration of Galanin N-Terminal fragment (1-15) 
induces depressant- and anxiogenic effects in rats. 
 
Galanin (GAL) is involved in several functions including mood regulation. Converging 
evidence implicates GAL and GAL receptors in anxiety- and depression-related 
behaviours. Intracerebroventricular (icv) GAL in animals results in enhanced 
depression-like behaviour in the forced swim test and in anxiolytic-like effects under 
stress conditions in the elevated plus maze. The GAL N-terminal fragment (1-15) 
[GAL(1-15)] also participates at central level and a differential role of GAL(1-15) 
compared with GAL has been proposed. In this work we have analysed if GAL(1-15) 
contributes to depression- and anxiety -related behaviours using four tests: forced 
swimming test (FST), elevated plus maze (EPM), open field (OF) and passive 
avoidance task (PA). 
 
In the first set of experiments four groups of rats (n=8-10) were treated three different 
times with icv GAL(1-15) 1, 3 and 6nmol or vehicle 15 minutes before the tests. 
Behavioural assessments were conducted with at least 1 week between tests. In the 
EPM the percentages of entries and time in open arms during 300 Sec were scored. In 
the OF test, the time and entries in the central square during 300 Sec were scored. The 
distance and spent were also determined. In the FST two sessions were conducted: a 15 
min pre-test followed 24 h later by a 5 min test. The total duration of immobility and 
active climbing was recorded during the second, 5 min test. 
In the second set the PA was performed. Rats (n=8-10) received icv GAL(1-15) 1, 3 and 
6nmol or vehicle 15 minutes prior the training session. Retention latency was tested 24 
h after training during 600 sec. 
 
In the OF test the administration of GAL(1-15) 3 and 6nmol significantly decreased the 
number of entries (p<0.01) and time spent (p<0.05) in the central square by 42% and 
39% respectively. However, in the EPM GAL(1-15) did not change any of the 
parameters analysed. Gal(1-15) didn’t change the Locomotor Activity in any test. In the 
FST GAL(1-15) 3 and 6nmol significantly increased immobility (p<0.01) and decreased 
the climbing behaviour (p<0.01) by 44% and 46% respectively. In the PA GAL(1-15) 
6nmol significantly decreased the retention latency (p<0.05). 
 
These results indicate that GAL(1-15) produces anxiogenic-like effects in the OF and 
depression-like behaviour in the FST, GAL(1-15) may also have an effect on emotional 
memory in PA. These results may give the basis for the development of novel 
therapeutic drugs targeting GAL(1-15) system for treatment of depression and anxiety 
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